Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $701.6 million.

  • Bioventus' Liabilities and Shareholders Equity fell 882.39% to $701.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 1070.67%. This contributed to the annual value of $728.0 million for FY2024, which is 1022.97% down from last year.
  • Latest data reveals that Bioventus reported Liabilities and Shareholders Equity of $701.6 million as of Q3 2025, which was down 882.39% from $706.8 million recorded in Q2 2025.
  • Bioventus' Liabilities and Shareholders Equity's 5-year high stood at $1.4 billion during Q4 2022, with a 5-year trough of $643.1 million in Q2 2021.
  • In the last 5 years, Bioventus' Liabilities and Shareholders Equity had a median value of $794.2 million in 2024 and averaged $888.3 million.
  • As far as peak fluctuations go, Bioventus' Liabilities and Shareholders Equity surged by 14791.63% in 2021, and later crashed by 4198.2% in 2023.
  • Over the past 5 years, Bioventus' Liabilities and Shareholders Equity (Quarter) stood at $1.2 billion in 2021, then increased by 11.97% to $1.4 billion in 2022, then plummeted by 40.92% to $810.9 million in 2023, then decreased by 10.23% to $728.0 million in 2024, then fell by 3.62% to $701.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $701.6 million in Q3 2025, compared to $706.8 million in Q2 2025 and $691.4 million in Q1 2025.